134 related articles for article (PubMed ID: 21266162)
21. [Quantity and distribution of CD44+/CD24- cells in breast cancer tissue and the cell lines].
Lü XQ; Suo Z; Ma CL; Xu KJ; Liu YS; Li HX
Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):441-4. PubMed ID: 19781189
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.
Wei HJ; Yin T; Zhu Z; Shi PF; Tian Y; Wang CY
Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):428-34. PubMed ID: 21813394
[TBL] [Abstract][Full Text] [Related]
23. Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition.
Li X; Kong X; Huo Q; Guo H; Yan S; Yuan C; Moran MS; Shao C; Yang Q
Cancer Sci; 2011 Jun; 102(6):1151-7. PubMed ID: 21371176
[TBL] [Abstract][Full Text] [Related]
24. The Hedgehog signaling pathway is associated with poor prognosis in breast cancer patients with the CD44+/CD24‑ phenotype.
Zhao H; Tang H; Xiao Q; He M; Zhao L; Fu Y; Wu H; Yu Z; Jiang Q; Yan Y; Jin F; Wei M
Mol Med Rep; 2016 Dec; 14(6):5261-5270. PubMed ID: 27779682
[TBL] [Abstract][Full Text] [Related]
25. ERalpha signaling through slug regulates E-cadherin and EMT.
Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Shetuni B; Barsky SH
Oncogene; 2010 Mar; 29(10):1451-62. PubMed ID: 20101232
[TBL] [Abstract][Full Text] [Related]
26. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
27. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types.
de Beça FF; Caetano P; Gerhard R; Alvarenga CA; Gomes M; Paredes J; Schmitt F
J Clin Pathol; 2013 Mar; 66(3):187-91. PubMed ID: 23112116
[TBL] [Abstract][Full Text] [Related]
28. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
30. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.
Osta WA; Chen Y; Mikhitarian K; Mitas M; Salem M; Hannun YA; Cole DJ; Gillanders WE
Cancer Res; 2004 Aug; 64(16):5818-24. PubMed ID: 15313925
[TBL] [Abstract][Full Text] [Related]
31. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
Lü X; Xu K; Lü H; Yin Y; Ma C; Liu Y; Li H; Suo Z
Ultrastruct Pathol; 2011 Apr; 35(2):72-8. PubMed ID: 21299347
[TBL] [Abstract][Full Text] [Related]
32. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Vellon L; Menendez JA
Cell Cycle; 2011 Nov; 10(22):3871-85. PubMed ID: 22127234
[TBL] [Abstract][Full Text] [Related]
33. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of CD44
Da Cruz Paula A; Leitão C; Marques O; Rosa AM; Santos AH; Rêma A; de Fátima Faria M; Rocha A; Costa JL; Lima M; Lopes C
Virchows Arch; 2017 Mar; 470(3):311-322. PubMed ID: 28116522
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
[TBL] [Abstract][Full Text] [Related]
36. Co-Expression of Cancer Stem Cell Markers Corresponds to a Pro-Tumorigenic Expression Profile in Pancreatic Adenocarcinoma.
Skoda J; Hermanova M; Loja T; Nemec P; Neradil J; Karasek P; Veselska R
PLoS One; 2016; 11(7):e0159255. PubMed ID: 27414409
[TBL] [Abstract][Full Text] [Related]
37. A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ; Wang S; Liu XA; Shen EC; Ding Q; Lu C; Xu J; Cao QH; Zhu HQ; Wang F
Chin Med J (Engl); 2008 Oct; 121(20):1980-6. PubMed ID: 19080260
[TBL] [Abstract][Full Text] [Related]
38. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC).
Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B
Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168
[TBL] [Abstract][Full Text] [Related]
39. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
[TBL] [Abstract][Full Text] [Related]
40. Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen‑ and doxorubicin‑induced autophagy.
Yenigun VB; Ozpolat B; Kose GT
Int J Mol Med; 2013 Jun; 31(6):1477-83. PubMed ID: 23589132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
